Clinical Focus

Quick Links

Publications

Current Issue

Alzheimer Disease Symptoms: More Than Memory Loss and Confusion

New Era Arrives for Disease Modification in Multiple Sclerosis

Searching for Off-Time Relief in Parkinson Disease

Exploring CB1, CB2 in Various Neurological Conditions

Phase III Study Brings Hope to ALS

Rapid Development of Migraine Therapies Offers New Hope

European Committee for Treatment and Research in Mulitple Sclerosis 2018

The 34th Congress of the European Committee for Treatment and Research in Mulitple Sclerosis (ECTRIMS) was held in Berlin, Germany, from October 10 to 12, 2018. The congress covered all the latest and exciting new developments in multiple sclerosis, including treatment, genetics, pathology, imaging, immunology, and epidemiology.

Ari Green, MD, MCR: Remyelination in Multiple Sclerosis

The medical director of the UCSF Multiple Sclerosis Center discussed the idea behind remyelination and shared his thoughts on what the best shot at developing a therapy might be.

Robert J. Fox, MD: Treating Progressive Multiple Sclerosis

The neurologist from Cleveland Clinic discussed the challenges of treating progressive MS, and shared his clinical experience with ibudilast.

Peter Calabresi, MD: Utilizing A Uniform Biomarker Assay

For the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.

Thomas Leist, MD: Resetting the Immune System With Cladribine

The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University discussed the concept of lymphocyte depletion to reset the immune system.

Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight Open

The smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.

Teriflunomide Slows Brain Atrophy In Patients At Risk for MS Conversion

Results suggested that for every 1% of brain volume lost, a 51.7% increase in risk of clinically definite MS conversion was observed.

Richard Rudick, MD: The CogEval App in Clinical Practice

The goal of the free application is to make cognitive assessments routine in multiple sclerosis treatment.

Remyelination As The Next Frontier in Multiple Sclerosis

The next important area of therapeutic development in MS appears to be in disease damage repair.

Alemtuzumab Shows Continuous Long-Term Effect on Multiple Sclerosis

The monoclonal antibody has shown continued success up to 8 years in clinical trials.

Peter Calabresi, MD: Clinically Validating Neurofilament Light

One of the highly debated topics at ECTRIMS 2018 was the use of the investigational biomarker, neurofilament light, in the clinic.

John Corboy, MD: The DISCO-MS Trial

The professor of neurology at Colorado University spoke about the ongoing phase IV trial to determine the safety of DMT discontinuation in MS.

Evobrutinib Significantly Reduces T1 Gd+ Lesions in Relapsing Multiple Sclerosis

This marks the first time a BTK inhibitor showed a clinical proof-of-concept in relapsing MS.

Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis

The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.

Thomas Leist, MD: Immune Reconstitution Therapy for Multiple Sclerosis

The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.

Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.

Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMS

The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.

Cladribine Tablets Safety Profile Reaffirmed With Long-Term Data

An updated safety analysis of the therapy in patients with relapsing MS, up to 10 years, has shown no new safety signals.

Richard Rudick, MD: Using Data to Personalize MS Care

The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.

John Corboy, MD: Taking Patients Off Of Disease-Modifying Therapy

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.

Earlier Treatment With Ocrelizumab Shows Favorable Results in Relapsing, Primary Progressive MS

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.